Immunology and Microbiology
Natural Killer Cell
100%
Synapse
39%
Secretion (Process)
36%
Perforin
24%
Target Cell
24%
Cytotoxicity
22%
Macrophage
21%
Cancer Cell
20%
Dendritic Cell
19%
Surface Property
17%
Interleukin 1
17%
Immune Response
15%
Monocyte
15%
Interferon Type I
13%
Interleukin 2
12%
Inflammasome
11%
Immunocompetent Cell
11%
CD16
10%
Cytokine
10%
Cellular Secretion
10%
Cell Surface
9%
Complement Membrane Attack Complex
9%
T Cell Activation
9%
Co-Stimulation
9%
Interleukin 15
9%
Granzyme B
9%
Internalization
9%
Tension
9%
RNA Sequence
9%
Rituximab
9%
Cell Mediated Cytotoxicity
9%
NOD-like Receptor
9%
Death Receptor
9%
Immunofluorescence
9%
Magnetism
9%
Prostaglandin E
9%
Capping Phenomenon
9%
T Cell
9%
Chédiak-Higashi Syndrome
9%
CD226
9%
Killer Cell
9%
Membrane Structure
9%
NLRP3 Inflammasome
9%
Cytolysis
9%
Leukocyte
9%
Dexamethasone
9%
Genetic Variability
9%
B Cell
9%
Lymphocytotoxicity
9%
Interleukin 18
7%
Cytokine Receptor
6%
Channel Gating
6%
Gasdermin D
6%
Cell Population
5%
Killer-Cell Immunoglobulin-Like Receptor
5%
Helminth
5%
Cytotoxic T Cell
5%
Caspase 1
5%
Biochemistry, Genetics and Molecular Biology
Surface Property
39%
Super-Resolution Microscopy
36%
Natural Killer Cell
35%
Macrophage
28%
Eicosanoid Receptor
28%
Secretion (Process)
21%
Alveolar Macrophage
20%
Immunocompetent Cell
18%
Synapse
15%
Membrane Topology
14%
Fc Receptor
14%
Cellular Secretion
10%
Genetic Divergence
9%
Imatinib
9%
Neurotropism
9%
Immunofluorescence
9%
Interleukin 15
9%
Myeloid
9%
Capping Phenomenon
9%
B Cell
9%
Intravenous Immunoglobulin
9%
Rituximab
9%
KIR2DS1
7%
Mitochondrion
7%
Optics
7%
Perforin
6%
Cytokine Receptor
6%
Interleukin 2
6%
Cytoskeleton
6%
Reconstruction
6%
Actin
5%
Medicine and Dentistry
Immunocompetent Cell
21%
Cancer Cell
19%
Synapse
15%
Perforin
14%
Cell Surface
12%
Target Cell
10%
Cytotoxicity
10%
T Cell
10%
Natural Killer Cell
10%
Macrophage
9%
Diseases
9%
Health
9%
Rituximab
9%
Cardiac Magnetic Resonance Imaging
9%
B Cell
9%
Stroma
9%
Nanotube
9%
Cell Mediated Cytotoxicity
9%
Leukocyte
9%
Imatinib Resistance
9%
Capping Phenomenon
9%
Chronic Myelogenous Leukemia
9%
Cellular Secretion
9%
Leukemia Cell
9%
Ligation
9%
Co-Stimulation
9%
Protein Transport
9%
Neoplasm
9%
Death Receptor
9%
T Cell Activation
9%
Lymphocyte
9%
Immunofluorescence
9%
T Lymphocyte Receptor
9%
Lymphocytotoxicity
9%
Radiation Therapy
9%
Granzyme B
8%
Secretion (Process)
6%
Receptor
6%
In Vitro
5%